Blog - News
The numbers are brutal: “Three years, one week, one day” of TB treatment — 23 tablets a day,” to fight the #1 killer in South Africa. Today, the New York Times published an op-ed by Dr. Uvi Naidoo about his three-year struggle to be cured of a severe form of MDR-TB that he contracted during his medical residency in South Africa. Dr. Naidoo’s fight against this awful disease is heartbreaking. And yet it’s all too common.
This past week, a group of about 500 people came together in the name of global development and advocacy for a five day conference. Running from July 18-July 22 and sponsored in part by Aeras, the conference offered a variety of programming including seminars, skill building workshops, plenaries, an advocacy day, a congressional reception, and a final gala.Here's what we learned!
In this guest post, Claire Wingfield—product development policy officer at PATH—writes about a new paper exploring why research and development (R&D) of high-priority health tools for diseases and conditions affecting low- and middle-income countries (LMICs) should be a critical component of the post-2015 development agenda.